American Century Companies Inc. Boosts Stake in Pfizer Inc. (NYSE:PFE)

American Century Companies Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,679,628 shares of the biopharmaceutical company's stock after purchasing an additional 75,245 shares during the quarter. American Century Companies Inc.'s holdings in Pfizer were worth $71,091,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Bank of America reiterated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Remove Ads

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

NYSE PFE traded up $0.05 during trading on Friday, reaching $25.06. The company's stock had a trading volume of 15,259,186 shares, compared to its average volume of 38,978,755. The business's fifty day moving average price is $26.09 and its 200-day moving average price is $26.97. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $142.10 billion, a price-to-earnings ratio of 17.77, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.